BFS
VKTX icon

Bare Financial Services’s Viking Therapeutics VKTX Stock Holding History

Bare Financial Services’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$975 Sell
25
-73
-74% -$2.36K ﹤0.01% 1396
2026
Q1 		$3.19K Buy
98
+27
+38% +$868 ﹤0.01% 825
2025
Q4 		$2.5K Buy
71
+59
+492% +$2.09K ﹤0.01% 788
2025
Q3 		$315 Buy
+12
New +$358 ﹤0.01% 1384

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Bare Financial Services's VKTX Position: Q2 2026 in Review

Bare Financial Services reduced its Viking Therapeutics (VKTX) stake by 74% in Q2 2026, selling an estimated $2.36K and leaving 25 shares worth $975. The position accounts for ﹤0.01% of the portfolio, ranked #1396.

Bare Financial Services first reported a position in VKTX in Q3 2025 and has held it in 4 quarters since. The position peaked at $3.19K in Q1 2026. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Bare Financial Services held 25 shares of Viking Therapeutics worth $975 as of Q2 2026.
  • Bare Financial Services sold 73 Viking Therapeutics shares in Q2 2026, an estimated $2.36K.
  • Viking Therapeutics made up ﹤0.01% of Bare Financial Services's portfolio in Q2 2026, its #1396 holding.
  • Bare Financial Services first reported a position in Viking Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Bare Financial Services's Viking Therapeutics position peaked at $3.19K in Q1 2026.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Bare Financial Services's 13F filing for Q2 2026, filed 27 Jul 2026.